BR112015012987A2 - composições compreendendo anticorpos anti-cd38 e lenalidomida - Google Patents

composições compreendendo anticorpos anti-cd38 e lenalidomida

Info

Publication number
BR112015012987A2
BR112015012987A2 BR112015012987A BR112015012987A BR112015012987A2 BR 112015012987 A2 BR112015012987 A2 BR 112015012987A2 BR 112015012987 A BR112015012987 A BR 112015012987A BR 112015012987 A BR112015012987 A BR 112015012987A BR 112015012987 A2 BR112015012987 A2 BR 112015012987A2
Authority
BR
Brazil
Prior art keywords
compositions
antibodies
lenalidomide
kits
subjects
Prior art date
Application number
BR112015012987A
Other languages
English (en)
Inventor
T Aftab Blake
Tomkinson Blake
C Hann Byron
G Martin Thomas Iii
Original Assignee
Sanofi Sa
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Univ California filed Critical Sanofi Sa
Publication of BR112015012987A2 publication Critical patent/BR112015012987A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

resumo patente de invenção: "composições compreendendo anticorpos anti-cd38 e lenalidomida". a presente invenção refere-se a composições e kits os quais compreendem anticorpos anti-cd38 e compostos de lenalidomida. também se refere a métodos para tratamento de cânceres, tal como um mieloma múltiplo, em sujeitos com as composições e os kits.
BR112015012987A 2012-12-07 2013-12-06 composições compreendendo anticorpos anti-cd38 e lenalidomida BR112015012987A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (1)

Publication Number Publication Date
BR112015012987A2 true BR112015012987A2 (pt) 2017-09-12

Family

ID=50884019

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012987A BR112015012987A2 (pt) 2012-12-07 2013-12-06 composições compreendendo anticorpos anti-cd38 e lenalidomida

Country Status (31)

Country Link
EP (2) EP3597191A1 (pt)
JP (2) JP6499971B2 (pt)
KR (2) KR102193045B1 (pt)
CN (1) CN105263520B (pt)
AR (1) AR093844A1 (pt)
AU (2) AU2013355064B2 (pt)
BR (1) BR112015012987A2 (pt)
CA (1) CA2893946A1 (pt)
CL (2) CL2015001558A1 (pt)
CY (2) CY1122478T1 (pt)
DK (1) DK2928495T3 (pt)
ES (1) ES2731548T3 (pt)
HK (1) HK1215536A1 (pt)
HR (1) HRP20191034T1 (pt)
HU (3) HUE044142T2 (pt)
IL (2) IL239234B (pt)
LT (2) LT2928495T (pt)
MX (2) MX366296B (pt)
MY (1) MY191601A (pt)
NL (1) NL301079I2 (pt)
NZ (1) NZ709215A (pt)
PH (1) PH12015501263A1 (pt)
PL (1) PL2928495T3 (pt)
PT (1) PT2928495T (pt)
RS (1) RS58829B1 (pt)
RU (1) RU2698911C2 (pt)
SG (3) SG10201913783PA (pt)
SI (1) SI2928495T1 (pt)
TW (2) TW201919699A (pt)
UA (1) UA118255C2 (pt)
WO (1) WO2014089416A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL300548A (en) 2015-05-20 2023-04-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
EA036789B1 (ru) 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
TWI800341B (zh) 2015-11-03 2023-04-21 美商健生生物科技公司 抗cd38抗體之皮下調配物及其用途
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
KR102286497B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019199133A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드의 경구용 코팅 정제 조성물
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
SG11202107319PA (en) * 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3160502A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
WO2023015170A2 (en) * 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US9040050B2 (en) * 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
HUE031956T2 (en) 2010-09-27 2017-08-28 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
CL2015001558A1 (es) 2015-10-02
SI2928495T1 (sl) 2019-07-31
JP2016506388A (ja) 2016-03-03
PL2928495T3 (pl) 2019-09-30
ES2731548T3 (es) 2019-11-15
IL239234B (en) 2021-05-31
KR102193045B1 (ko) 2020-12-18
CN105263520A (zh) 2016-01-20
AR093844A1 (es) 2015-06-24
UA118255C2 (uk) 2018-12-26
JP2019070020A (ja) 2019-05-09
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
KR20200143503A (ko) 2020-12-23
CA2893946A1 (en) 2014-06-12
CY1122478T1 (el) 2021-01-27
AU2013355064A1 (en) 2015-07-09
EP2928495B1 (en) 2019-03-27
EP2928495A1 (en) 2015-10-14
MX2019008065A (es) 2019-09-23
IL239234A0 (en) 2015-07-30
CY2020040I1 (el) 2021-03-12
HUS2000051I1 (hu) 2020-12-28
SG11201504315WA (en) 2015-07-30
CY2020040I2 (el) 2021-05-05
RU2698911C2 (ru) 2019-09-02
WO2014089416A1 (en) 2014-06-12
TWI670062B (zh) 2019-09-01
CN105263520B (zh) 2020-03-13
EP3597191A1 (en) 2020-01-22
PH12015501263A1 (en) 2015-08-17
IL282542A (en) 2021-06-30
HUE044142T2 (hu) 2019-09-30
JP6499971B2 (ja) 2019-04-10
KR20150091165A (ko) 2015-08-07
HUS2000050I1 (hu) 2020-12-28
SG10201913783PA (en) 2020-03-30
TW201919699A (zh) 2019-06-01
RU2015127089A (ru) 2017-01-13
PT2928495T (pt) 2019-07-04
MX2015007189A (es) 2016-03-21
SG10201704536PA (en) 2017-07-28
CL2018003292A1 (es) 2019-02-01
RS58829B1 (sr) 2019-07-31
HK1215536A1 (zh) 2016-09-02
MY191601A (en) 2022-07-01
LT2928495T (lt) 2019-07-10
DK2928495T3 (da) 2019-06-24
MX366296B (es) 2019-07-04
AU2013355064B2 (en) 2018-05-24
EP2928495A4 (en) 2016-05-11
LTPA2020537I1 (lt) 2020-12-28
AU2018211258A1 (en) 2018-08-16
NZ709215A (en) 2020-08-28
HRP20191034T1 (hr) 2019-08-23

Similar Documents

Publication Publication Date Title
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
CY1122278T1 (el) Αντι il-36r αντισωματα
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
TN2014000134A1 (en) Therapeutic peptides
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2016001154A1 (es) Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201400178A1 (ru) Лечение рака молочной железы
EA201590887A1 (ru) Композиция
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2015007518A (es) Metodos para tratar el prurito.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
IL232194A0 (en) An improved iontophoretic cross-linking mixture for use in the treatment of keratoconus
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
EA201491581A1 (ru) Везикулярные композиции
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EA201591449A1 (ru) Способы получения противораковых композиций
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2015012381A (es) Inmunogenos fungicos y materiales y metodos relacionados.
EA201400970A1 (ru) Новые композиции для лечения амиотрофического бокового склероза
TN2014000207A1 (en) Anti il-36r antibodies
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]